Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

(2020) Patricia Martin‐Romano et al.   Cancer Medicine

Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy

(2020) Maxime Frelaut et al.   BIODRUGS

Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition

(2020) Lucas Basler et al.   CLINICAL CANCER RESEARCH

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

(2019) Roberto Ferrara et al.   Journal of Thoracic Oncology

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

(2019) Jarrett J Failing et al.   Future Oncology

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma

(2019) Nabil Elshafeey et al.   Nature Communications

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy

(2019) Ines Pires da Silva et al.   CANCER

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

(2018) M. Tazdait et al.   EUROPEAN JOURNAL OF CANCER

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy

(2018) Christine M. Parseghian et al.   JOURNAL OF IMMUNOTHERAPY

Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

(2018) Sharyn I. Katz et al.   Journal of Thoracic Oncology

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

(2018) Jenny H. Lee et al.   JAMA Oncology

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

(2018) Marie-Léa Gauci et al.   CLINICAL CANCER RESEARCH

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

(2018) Daichi Fujimoto et al.   Journal of Thoracic Oncology

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

(2017) Laetitia Marisa et al.   JNCI-Journal of the National Cancer Institute

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

(2017) Giovanni Germano et al.   NATURE

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review

(2017) Young Kwang Chae et al.   Oncotarget

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors

(2017) Laetitia Marisa et al.   JNCI-Journal of the National Cancer Institute

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

(2017) Roman Groisberg et al.   Journal for ImmunoTherapy of Cancer

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH